Evidence map›Paper›PMID 41758880›Full record

Observational studyPloS one2026

Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study.

Franziska Meyer, Stephan Traidl, Milad Ameri, Anita Dreher, Nevine Abu-Rashed-Kufs, Jan Vontobel, Matthias Möhrenschlager, Hans-Werner Duchna, Felicia Sandberg, Marie-Charlotte Brüggen

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Franziska MeyerHochgebirgsklinik Davos, Davos, Switzerland.
Stephan TraidlFaculty of Medicine, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-4806-599X
Milad AmeriFaculty of Medicine, University of Zurich, Zurich, Switzerland.
Anita DreherChristine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
Nevine Abu-Rashed-KufsHochgebirgsklinik Davos, Davos, Switzerland.
Jan VontobelHochgebirgsklinik Davos, Davos, Switzerland.
Matthias MöhrenschlagerHochgebirgsklinik Davos, Davos, Switzerland.
Hans-Werner DuchnaHochgebirgsklinik Davos, Davos, Switzerland.
Felicia SandbergCardio-CARE, Medizincampus Davos, Davos, Switzerland.ORCID https://orcid.org/0000-0002-3535-5122
Marie-Charlotte BrüggenFaculty of Medicine, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 can have diverse clinical manifestations, ranging from asymptomatic infection to critical illness with multiorgan involvement. While many patients recover fully, others develop long-COVID, a heterogeneous condition marked by persistent symptoms beyond the acute phase. The immunological pathomechanisms between long-COVID and other post-acute recovery states remain unclear.

objectiveTo characterize and compare clinical, pulmonary, and proteomic profiles of patients with long-COVID (LC) and those recovering from severe COVID-19 without long-COVID (post-severe-COVID, PC), and to evaluate the predictive potential of machine learning-based biomarker analysis.

methodsIn this monocentric, prospective observational study with a cross-sectional design, patients undergoing rehabilitation were included at admission. Clinical data, detailed symptom profiles, and lung function testing, including diffusing capacity of the lungs, were collected. Serum proteomics covering immune response and inflammation panels was performed, and a Random Forest classifier was applied to identify biomarkers differentiating LC and PC.

resultsLC (n = 24) patients were younger (52 years vs. 58 years in PC), predominantly female (66.7% vs. 30.0% in PC), and reported fatigue, neurocognitive symptoms, and exercise intolerance, whereas PC (n = 40) patients showed greater pulmonary impairment, as shown by reduced diffusing capacity (46% vs. 72.5% in LC p<0.001). Proteomic profiling revealed distinct immune and inflammatory signatures between groups. Applying a random forest classification algorithm, we were able to distinguish between the LC and the PC group with a high degree of accuracy of around 89%, using LAMP3 (Lysosome-associated membrane glycoprotein 3), CKAP4 (cytoskeleton associated protein 4) and KRT19 (Keratin 19).

conclusionsThis study introduces a novel characterization of patients recovering from severe COVID-19 without long-COVID, enabling clearer differentiation between persistent and recovering trajectories. Combining clinical data, pulmonary function, and proteomic machine learning analysis provides insight into post-acute COVID-19 biology and identifies candidate biomarkers for improved diagnosis.

Indexed as

COVID-19Machine LearningProteomicsAdultAgedBiomarkersCross-Sectional StudiesDiagnosis, DifferentialFemaleHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeProspective StudiesSARS-CoV-2Biomarkers

Identifiers

PMID41758880
PMCPMC12948100

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.